SQSTM1 and ovarian serous adenocarcinoma: Abnormal amplification and phosphorylation of p62/SQSTM1 have been implicated in tumor progression and resistance therapy, such as in hepatocellular carcinoma (Saito et al., 2016), and platinum-resistant cells of high-grade serous ovarian cancer (Nguyen et al., 2017).